Skip to content

Idiopathic Generalized Epilepsy Syndromes

Idiopathic Generalized Epilepsy Syndromes: Clinical Features and Long-term Outcomes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06388174
Enrollment
200
Registered
2024-04-29
Start date
2023-01-01
Completion date
2033-12-31
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Epilepsy, Idiopathic Generalized

Brief summary

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

Detailed description

the Long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (ADHD) and learning disabilities.

Interventions

None listed

Sponsors

Shen Chun-Hong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
4 Years to 40 Years

Inclusion criteria

* Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy. * Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria. * Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed. * Sign the informed consent forms.

Exclusion criteria

* Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy. * Lost to follow-up

Design outcomes

Primary

MeasureTime frameDescription
The proportion of drug-resistent epilepsythrough study completion, an average of 1 yearWe defined drug-resistant cases as those patients who have failed two or more trials of broad-spectrum ASMs or those otherwise indicated in IGE syndromes
The proportion of seizure freedomthrough study completion, an average of 1 yearWe defined seizure freedom according to the International League Against Epilepsy (ILAE) definition

Secondary

MeasureTime frameDescription
The proportion of psychiatric comorbiditythrough study completion, an average of 1 yearThe psychiatric comorbidities mainly include anxiety and depression, which are evaluated by Hamilton anxiety scale and Hamilton depression scale, respectively.
The proportion of psychosocial outcomethrough study completion, an average of 1 yearsuch as university entrance, marry
The proportion of seizure relapse after antiseizure medication withdrawnthrough study completion, an average of 1 yearAntiseizure medication withdrawn should be recommended by epilepsy experts

Countries

China

Contacts

Primary ContactChunhong Shen
shen_neurology@zju.edu.cn+86 0571 87783872

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026